TITLE

Glucagon-like peptide-1 receptor agonists for intensifying diabetes treatment

AUTHOR(S)
Bush, Michael A.
PUB. DATE
September 2011
SOURCE
Journal of Family Practice;Sep2011 Supplement 1, Vol. 60, pS11
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the efficacy of glucagon-like peptide-1 receptor (GLP-1R) agonists in diabetic treatment. It mentions that GLP-1R agonist with the combination of lifestyle management can reduce the glycated hemoglobin (A1C) level by 0.5% to 1.5%. It states the effectiveness of GLP-1R agonist as an add-on therapy to metformin or with the combination to other agents is being extensively investigated. It adds that GLP-1R agonist also lowers blood glucose.
ACCESSION #
67147176

 

Related Articles

  • Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets. Devries, J. Hans; Bain, Stephen C.; Rodbard, Helena W.; Seufert, Jochen; D'Alessio, David; Thomsen, Anne B.; Zychma, Marcin; Rosenstock, Julio // Diabetes Care;Jul2012, Vol. 35 Issue 7, p1446 

    OBJECTIVE--We evaluated the addition of liraglutide to metformin in type 2 diabetes followed by intensification with basal insulin (detemir) if glycated hemoglobin (A1C) ≥7%. RESEARCH DESIGN AND METHODS--In 988 participants from North America and Europe uncontrolled on metformin 6...

  • Appraisal of Saxagliptin as Treatment of Type 2 Diabetes. Mikhail, Nasser; Cope, Dennis // Current Drug Therapy;May2010, Vol. 5 Issue 2, p111 

    The antidiabetic effect of the dipeptidyl peptidase 4 (DPP-4) inhibitor saxagliptin depends on the prolongation of action of the 2 incretin hormones: glucagon like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) by preventing their rapid degradation by the enzyme DPP-4. The use of...

  • Safety, tolerability, and nonglycemic effects of incretin-based therapies. Keith Campbell, R.; Cobble, Michael E.; Reid, Timothy S.; Shomali, Mansur E. // Journal of Family Practice;Sep2010 Supplement, Vol. 59, pS20 

    The article focuses on the tolerability, safety, and nonglycemic effects of incretin-based therapies for the treatment of type 2 diabetes mellitus (T2DM). It states that the use of glucose-lowering medications which reduced associated risk factors and indicates favorable safety profile shows...

  • Practical applications of therapy with a glucagon-like peptide- 1 receptor agonist. Shomali, Mansur E. // Journal of Family Practice;Sep2009 Treating Patients, Vol. 58, pS35 

    The article discusses various studies which showed medical applications of glucagon-like peptide-1 (GLP-1) receptor agonist to treat patients with type 2 diabetes mellitus (T2DM) in the U.S. It found that the treatment regimen is effective after the initiation of lifestyle management and...

  • What next when metformin isn't enough for type 2 diabetes? Hawes, Emily M.; Wehby, Joseph; Mounsey, Anne // Journal of Family Practice;Feb2016, Vol. 65 Issue 2, p85 

    This patient-centered case vignette offers insight into how best to choose among additional oral agents, basal insulin, or the newer GLP-1 receptor agonists.

  • Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables. Li-Nong Ji; Ju-Ming Lu; Xiao-Hui Guo; Wen-Ying Yang; Jian-Ping Weng; Wei-Ping Jia; Da-Jin Zou; Zhi-Guang Zhou; De-Min Yu; Jie Liu; Zhong-Yan Shan; Yu-Zhi Yang; Ren-Ming Hu; Da-Long Zhu; Li-Yong Yang; Li Chen; Zhi-Gang Zhao; Qi-Fu Li; Hao-Ming Tian; Qiu-He Ji // BMC Public Health;2013, Vol. 13 Issue 1, p1 

    Background: The prevalence of type 2 diabetes mellitus (T2DM) is increasing rapidly among Chinese adults, and limited data are available on T2DM management and the status of glycemic control in China. We assessed the efficacy of oral antidiabetes drugs (OADs), glucagon-like peptide-1 (GLP-1)...

  • Glucagon-like peptide-1 receptor agonist use in type 1 diabetes. Flanagan, Daniel // Diabetes Digest;2014, Vol. 13 Issue 3, p114 

    The article discusses studies on the management of Type 1 diabetes (T1D). It references published studies including one in "Diabetes Care" about the effects of exanatide when added to insulin therapy for improving the beta-cell function of T1D patients and one in "Diabetic Medicine" on the...

  • Linagliptin linked to better blood sugar in black patients with type 2 diabetes. Costa, Samantha; Fisher, Stacey L.; Foster, Melissa // Endocrine Today;Jun2012, Vol. 10 Issue 6, p17 

    The article focuses on the effectiveness of linagliptin in improving the blood sugar levels of African American patients with type 2 diabetes, as discussed by researcher James Thrasher at the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific and Clinical Congress...

  • Missing the Point: Substituting Exenatide for Nonoptimized Insulin. Rosenstock, Julio; Fonseca, Vivian // Diabetes Care;Nov2007, Vol. 30 Issue 11, p2972 

    The author comments on the findings of a study on the safety of substituting exenatide for insulin therapy. He explains the effects of withdrawal of insulin therapy on glycemic control of patients with diabetes. He argues that the glycemic control of patients at the end of the study was poor...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics